* Aileron Therapeutics Inc reported a quarterly adjusted loss of 45 cents per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of -39 cents. The lone analyst forecast for the quarter was for a loss of 42 cents per share.
* Reported revenue was zero; analysts expected zero.
* Aileron Therapeutics Inc's reported EPS for the quarter was a loss of 45 cents.
* The company reported a quarterly loss of $8.94 million.
* Aileron Therapeutics Inc shares had fallen by 33.2% this quarter and lost 39.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 169.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Aileron Therapeutics Inc is $13.00 This summary was machine generated from LSEG data August 15 at 12:39 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.42 -0.45 Missed
Mar. 31 2024 -0.14 -0.86 Missed
Dec. 31 2023 -0.16 -1.54 Missed
-0.40
Comments